Latest Headlines

  1. AST Names Industry Veteran Jon Lenihan As Chief Commercial Officer 8/31/2026
  2. AES Cleanroom Technology Panels Earn FM 4882 Approval, Addressing The Cleanroom Risk That Fire Ratings Miss 8/27/2026
  3. 4th Cell Therapy for Autoimmune Disease Summit 8/27/2026

    As cell therapy for autoimmune disease transitions from breakthrough clinical case studies to broad clinical validation, developers are racing to overcome challenges around safety, scalability, durability of response, and patient access while advancing the next generation of immune reset therapies.

  4. Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy 8/25/2026

    Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim Schuckman as its first Chief Commercial Officer (CCO). Schuckman joined the company on Monday 17 August in a newly created executive role that reflects Avance Clinical’s continued growth, deeper client partnerships, and expanding presence across North America, Asia, and Europe.

  5. Landmark Bio And Syngoi Technologies To Operate As Artis BioSolutions, An End-To-End Gene-To-GMP Platform For Genetic Medicines 7/29/2026

    Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name. 

  6. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.

  7. FUJIFILM Biosciences And NextCell Launch New Commercial Platform Comprised Of RUO Stromal Cells And Cell Culture Media 7/27/2026
  8. Esco Lifesciences To Showcase Innovative Laboratory And Pharmaceutical Solutions At ISPE Singapore Conference & Exhibition 2026 7/17/2026

    Esco Lifesciences is pleased to announce its participation in the ISPE Singapore Conference & Exhibition 2026, taking place on 20–21 August 2026 at Suntec Singapore. Visitors are invited to meet the team at Booth 811 to explore the latest technologies supporting pharmaceutical manufacturing, aseptic processing, and laboratory operations.

  9. RoosterBio And Applied StemCell Partner To Advance Scalable iPSC-Based Bioprocess Solutions 7/8/2026

    Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions.

  10. RoosterBio And Qkine Partner To Deliver A Single-Source Platform Of Cells, Media, And Growth Factors To U.S. Customers 7/7/2026

    RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins.